Vicore Pharma (Buy, TP: SEK38.00) - Focus on ASPIRE recruitment
The Q4 report was a non-event in our opinion, and we expect the market to focus on the recruitment pace for the ongoing phase IIb ASPIRE trial in IPF. The trial started recruiting in H2 2024 and c32 of a total 92 clinics are now actively recruiting patients. We expect the trial recruitment to be completed in early 2026 and data read-out in H1 2027 (52 weeks of treatment). We reiterate our BUY and SEK38 target price.Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.